Welcome!

Websphere Authors: Pat Romanski, Elizabeth White, Bob Gourley, Gilad Parann-Nissany, Liz McMillan

News Feed Item

Top Ten Companies in DNA Sequencing

NEW YORK, Oct. 17, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Top Ten Companies in DNA Sequencing

http://www.reportlinker.com/p01013573/Top-Ten-Companies-in-DNA-Sequencin...

 

INTRODUCTION

 

The story of molecular biology is being both written and printed by sequencing tools—various chapters being currently authored by oncologists, ID experts, pathologists, and so forth. The narrative is understood by only those select few who have the cross discipline knowledge to comprehend what the sequencing tools output, and who also have the niche domain experience to act upon knowledge of that data. Recently, this story has begun to change as low cost next generation sequencing democratizes genome data, allowing a politics and commerce of inclusion, to enter the lab and now also the clinic.

 

Diagnostic manufacturers can now afford to develop sequencing tools as diagnostic shortcuts. The clinician does not need to understand the mathematical underpinnings of 16SrRNA coverage for phylogeny to run a rapid anthrax test.

 

Tandem repeats and retrotransposons have been conveniently converted into a "plus" or "minus" sign—a red light/green light clinical decision.

 

When Watson and Crick let the genie out of the research bottle, it was inevitable that this day would arrive—the only question was when it would happen. The types of automation that enabled cost efficiencies in sequencing tools have become decision tree shortcuts in the clinic, whereupon the first tangible fruits from the promise of personalized medicine have become apparent.

 

DNA sequencing is a strategic genomics tool that allows us to study how the genome varies among individuals and how that variation correlates to disease. Sequencing technologies are a critical part of today's life-science industry, affecting a wide range of activity from drug discovery to diagnostics. This focused document profiles the top 10 companies of the industry and explores the underlying technologies driving the industry's growth. Each technology is analyzed to determine its market status, impact on future market segments, and future growth potential. It should be noted that sequencing costs may only contribute 10% to 20% of a typical biomedical projects overall costs.

 

Of significance is the large occurrence of collaboration and co-ownership among the top players. Certain individuals, such as Mike Hunkapller and George Church, appear and reappear in several of the leading companies as co-founder, adviser or board member. But investment in seemingly rival efforts is also unusually high, underscoring both the connected nature of the research and commercial community, and also a "quantitative easing" or de-risking of being on the right team when the eventual winners are crowned in this high stakes field.

For this top 10 report, many factors were considered when selecting the companies. In general, chosen companies have a solid foundation built around their sequencing technology and have done an excellent job strategically positioning themselves into one (or many) of the facets of the industry.

 

In a reply to BCC from one of the top sequencing industry leaders, George Church explains in more detail some of the technological specifics to success. Next generation sequencing (NGS) systems are evolving rapidly, meaning this should be a core area of focus for a company should they want to excel now and in the near future.

 

Of the NGS systems, benchtop sequencers have a good niche currently. Although they can't process as much as the larger high-throughput systems, being smaller has its obvious advantages. In the long term, benchtop sequencers may end up getting squeezed out of their niche however, finding no room for successful commercialization between the large high-throughput systems and handheld or portable sequencers which are based around nanopore technology.

 

At this stage there are several different approaches different companies are working on concerning nanopore-based technologies. Leading the way in this sector of sequencing will certainly help strengthen any company and their competitive position. Many companies are competing, and to a certain extent this is a race of scaling, that is, who can get the most nanopores into the smallest area.

 

One of the problems that arise from the sequencing process is the flood of data that results. A key issue to note is just how well informatics will be able to handle this data flood. As read lengths become longer and more accurate, the informatics becomes easier. Interpretation of the data is another issue that arises, but focusing on medically actionable determinations should simplify rather than complicate the interpretation of results.

 

Another point to consider is whole genome sequencing, a goal for many. Applications from this process becoming available everywhere at low cost aren't too far into the future at the moment. One application has already emerged, a test for 2,400 highly predictive medical genetic diseases. This is superior to exome testing as these have the serious flaw of missing phasing information. For example, if a genome has mutations on say exon number 2 and exon number 7 of a gene, the exome doesn't distinguish between two hits in one gene copy (the other copy is fine) vs. hits in both copies (no healthy copies).

 

Given these criteria to success, along with other factors which BCC chose to examine, BCC has selected these 10 companies for this report that we feel are deserving of recognition and are leaders in their industry, This list includes:

 

Agilent Technologies Inc.

Genia

International Business Machines Corp.

Illumina Inc.

Knome Inc.

Life Technologies

Oxford Nanopore Technologies

Pacific Biosciences

Raindance Technologies Inc.

Roche Holding AG.

 

As any top 10 list is invariably subjective, there are also several companies profiled in less detail. These companies were on the bubble, or should be watched in the near future.

 

STUDY GOALS AND OBJECTIVES

 

This document is a specialty report related to the BCC Research report BIO045D authored by John Bergin. The goal of this document is to provide a more in-depth look at the top tier DNA sequencing companies as well as some of the second tier companies to look for in the near future, and to note the technological changes within the DNA sequencing industry that are sure to play a role in the years to come.

 

More specifically, the objectives include identifying companies that are considered the leaders in their field and the technological means these companies are using to exploit their markets and dominate their field. Key technology points explored include:

 

How the NGS (next generation sequencing) benchtop systems will do versus the larger, high throughput systems.

How well NGS systems will penetrate into diagnostics.

Which up and coming nanopore-based technologies will emerge and how will this affect market applications.

How well will sequencing informatics be able to solve the data flood.

When will mass whole genome sequencing applications emerge.

 

Other major factors used to determine top companies in the field include:

 

Alliance, merger, and acquisition strategy.

Financing.

Intellectual property (patent) portfolio.

 

INTENDED AUDIENCE

 

This study will be of particular interest to life-science research tools suppliers, pharmaceutical, diagnostics, nanotechnology, bioinformatics, semiconductor, and biotechnology companies. It will also be valuable to companies involved in genome sequencing projects, sequencing centers, manufacturers of microarrays, suppliers of molecular diagnostics assays, bioinformatics companies, and cancer researchers and clinicians. As this report is a profiling of top companies in the DNA sequencing field, the main audience should also include executive management personnel and marketing and financial analysts.

 

SCOPE

 

The scope of this report is focused on a select 10 companies in DNA sequencing, and the key areas in the field that are driving industry growth allowing these companies to succeed. These areas include Sanger, next-generation, and emerging sequencing technologies; the markets for sample preparation products, sequencing instruments and consumables; and bioinformatics and sequencing services. A key area BCC also explores is industry structure, noting strategic alliances and acquisitions along with pertinent patent information.

 

METHODOLOGY

 

Based on primary and secondary market analysis, this report analyzes the top 10 companies in DNA sequencing as well as some additional companies worth recognizing.

 

 

 

TABLE OF CONTENTS

 

CHAPTER 1 INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 2

INTENDED AUDIENCE 3

SCOPE 3

METHODOLOGY 3

RELATED BCC REPORTS 3

BCC ONLINE SERVICES 4

DISCLAIMER 4

CHAPTER 2 DNA SEQUENCING TECHNOLOGY OVERVIEW 6

HISTORY 6

COST BREAKDOWN 7

CURRENT TECHNOLOGY OVERVIEW 7

TABLE 1 LIFE CYCLE OF DNA SEQUENCING TECHNOLOGIES 7

SANGER SEQUENCING 8

NEXT GENERATION SEQUENCING (NGS) 8

EMERGING SEQUENCING 8

TABLE 2 SEQUENCING INSTRUMENT COMPETITORS BY TECHNOLOGY 9

SANGER SEQUENCING 9

NEXT GENERATION SEQUENCING 10

NEXT GENERATION APPLICATIONS PARTIALLY ENABLED BY LOWER COSTS 10

NGS INSTRUMENT MARKET 11

TABLE 3 NGS INSTRUMENT MARKET SHARE IN 2011 ($ MILLIONS/%) 11

EMERGING SEQUENCING TECHNOLOGIES 12

TABLE 4 EMERGING SEQUENCING TECHNOLOGIES 12

TABLE 5 TOP COMPANIES IN EMERGING SEQUENCING INDUSTRY 13

BENCHTOP SEQUENCERS 13

TABLE 6 BENCHTOP SEQUENCING TECHNOLOGIES 13

SAMPLE PREPARATION REAGENTS AND KITS 13

TABLE 7 SEQUENCING SAMPLE PREPARATION COMPANY POSITIONING 14

SEQUENCE CAPTURE INDUSTRY 14

BIOINFORMATICS TECHNOLOGIES 14

TABLE 8 NGS SEQUENCING BIOINFORMATICS WORKFLOW 15

SEQUENCING SERVICES 16

CHAPTER 3 MARKET SUMMARY 18

MARKET GROWTH 18

TABLE 9 DNA SEQUENCING KEY GROWTH DRIVING FORCES 18

OVERALL MARKET 19

TABLE 10 GLOBAL VALUE OF SEQUENCING PRODUCTS AND SERVICES BY TYPE, THROUGH

2016 ($ MILLIONS) 19

INSTRUMENTS AND CONSUMABLES 19

TABLE 11 GLOBAL VALUE OF THE SEQUENCING INSTRUMENTS AND CONSUMABLES

MARKET BY PRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 19

INSTRUMENTS 20

TABLE 12 GLOBAL VALUE OF SEQUENCING INSTRUMENTS BY PLATFORM, THROUGH 2016

($ MILLIONS) 20

CONSUMABLES 20

SEQUENCING SERVICES 21

TABLE 13 GLOBAL VALUE OF SEQUENCING SERVICES BY END-USER MARKET, THROUGH

2016 ($ MILLIONS) 21

CLINICAL DIAGNOSTICS 21

R&D, PHARMA, BIOTECH 22

WORKFLOW PRODUCTS 22

SAMPLE PREP 22

BIOINFORMATICS 23

GLOBAL SEQUENCING MARKET BROKEN DOWN BY REGION 23

CHAPTER 4 SEQUENCING PATENT ANALYSIS 26

FIGURE 1 SEQUENCING PATENTS, 2001–2011 (NO. OF PATENTS) 26

FIGURE 2 SEQUENCING PATENTS BY REGION, 2001–2011 (NO. OF PATENTS) 27

FIGURE 3 EMERGING SEQUENCING COMPANY PATENTS BY REGION 28

CHAPTER 5 THE TOP 10 COMPANIES IN DNA SEQUENCING 31

AGILENT TECHNOLOGIES INC. 31

STRATEGIC ALLIANCES 32

FINANCIALS 33

KEY MANAGEMENT 33

GENIA 33

TABLE 14 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING 34

TECHNOLOGY 34

KEY MANAGEMENT 35

INTERNATIONAL BUSINESS MACHINES CORP. 35

KEY MANAGEMENT 37

ILLUMINA, INC. 37

ALLIANCES, MERGERS, AND ACQUISITIONS 38

ILLUMINA AND NGS 39

TABLE 15 ILLUMINA SEQUENCING PORTFOLIO BY INSTRUMENT ($ PER YEAR) 39

KEY MANAGEMENT 40

KNOME INC. 40

TABLE 16 KNOME'S BREAKDOWN OF VARIANTS 41

STRATEGIC ALLIANCES 41

KEY MANAGEMENT 42

LIFE TECHNOLOGIES INC. 42

ION TORRENT TECHNOLOGY 44

SANGER SEQUENCING 44

TABLE 17 LIFE TECHNOLOGIES' 3500DX INSTRUMENTS 45

NGS 45

TABLE 18 5500 SERIES GENETIC ANALYSIS SYSTEMS SPECIFICATIONS 45

THIRD GENERATION SEQUENCING 46

KEY ACQUISITIONS 46

MANAGEMENT 47

OXFORD NANOPORE TECHNOLOGIES 47

FINANCE HISTORY 48

TECHNOLOGY 48

KEY MANAGEMENT 49

PACIFIC BIOSCIENCES 49

ALLIANCES 51

Gen-Probe 51

Cycle Computing 51

LI-COR 51

Others 51

FINANCIALS 52

INITIAL PUBLIC OFFERING 52

EMPLOYEES AND LAYOFFS 52

INTELLECTUAL PROPERTY 52

MANAGEMENT 53

RAINDANCE TECHNOLOGIES INC. 53

TECHNOLOGY 53

SEQUENCE CAPTURE PANELS 54

TABLE 19 RAINDANCE RESEARCH SCREENING PANELS 54

STRATEGIC ALLIANCES 55

TABLE 20 RAINDANCE STRATEGIC ALLIANCES 55

RECENT FINANCES 56

MANAGEMENT 56

ROCHE HOLDING AG 57

TABLE 21 ROCHE DIAGNOSTICS SALES, BY REGION 2011 (%) 57

TABLE 22 ROCHE 454 SEQUENCING SYSTEMS COMPARISON 58

NIMBLEGEN 58

FLUIDIGM 59

IBM 59

MANAGEMENT 60

OTHER COMPANIES TO WATCH 60

BGI 60

COMPLETE GENOMICS INC. 61

DANAHER 62

FLUIDIGM CORPORATION 62

GEN-PROBE INC. 63

HELICOS BIOSCIENCES CORPORATION 63

NUGEN TECHNOLOGIES INC. 64

 

LIST OF TABLES

TABLE 1 LIFE CYCLE OF DNA SEQUENCING TECHNOLOGIES 7

TABLE 2 SEQUENCING INSTRUMENT COMPETITORS BY TECHNOLOGY 9

TABLE 3 NGS INSTRUMENT MARKET SHARE IN 2011 ($ MILLIONS/%) 11

TABLE 4 EMERGING SEQUENCING TECHNOLOGIES 12

TABLE 5 TOP COMPANIES IN EMERGING SEQUENCING INDUSTRY 13

TABLE 6 BENCHTOP SEQUENCING TECHNOLOGIES 13

TABLE 7 SEQUENCING SAMPLE PREPARATION COMPANY POSITIONING 14

TABLE 8 NGS SEQUENCING BIOINFORMATICS WORKFLOW 15

TABLE 9 DNA SEQUENCING KEY GROWTH DRIVING FORCES 18

TABLE 10 GLOBAL VALUE OF SEQUENCING PRODUCTS AND SERVICES BY TYPE, THROUGH

2016 ($ MILLIONS) 19

TABLE 11 GLOBAL VALUE OF THE SEQUENCING INSTRUMENTS AND CONSUMABLES

MARKET BY PRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 19

TABLE 12 GLOBAL VALUE OF SEQUENCING INSTRUMENTS BY PLATFORM, THROUGH 2016

($ MILLIONS) 20

TABLE 13 GLOBAL VALUE OF SEQUENCING SERVICES BY END-USER MARKET, THROUGH

2016 ($ MILLIONS) 21

TABLE 14 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING 34

TABLE 15 ILLUMINA SEQUENCING PORTFOLIO BY INSTRUMENT ($ PER YEAR) 39

TABLE 16 KNOME'S BREAKDOWN OF VARIANTS 41

TABLE 17 LIFE TECHNOLOGIES' 3500DX INSTRUMENTS 45

TABLE 18 5500 SERIES GENETIC ANALYSIS SYSTEMS SPECIFICATIONS 45

TABLE 19 RAINDANCE RESEARCH SCREENING PANELS 54

TABLE 20 RAINDANCE STRATEGIC ALLIANCES 55

TABLE 21 ROCHE DIAGNOSTICS SALES, BY REGION 2011 (%) 57

TABLE 22 ROCHE 454 SEQUENCING SYSTEMS COMPARISON 58

 

LIST OF FIGURES

FIGURE 1 SEQUENCING PATENTS, 2001–2011 (NO. OF PATENTS) 26

FIGURE 2 SEQUENCING PATENTS BY REGION, 2001–2011 (NO. OF PATENTS) 27

FIGURE 3 EMERGING SEQUENCING COMPANY PATENTS BY REGION 28

 

 

 

To order this report:

Genomics Industry: Top Ten Companies in DNA Sequencing

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.